Azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission
The present disclosure relates to certain novel compounds of Formula (I) and to their utility in modulation of levels of monoamines, dopamine, norepinephrine and serotonin, in cerebral cortical areas of the mammalian brain, and more specifically for the treatment of central nervous system disorders.
1. A compound of Formula I:
or a pharmaceutically acceptable salt thereof,
wherein
R 4 is F or CH 3 ,
R 5 is H or C 1 -C 4 alkyl substituted with 0, 1, 2 or 3 F, and
n is 0, 1, 2 or 3.
2. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof,
wherein
n is 0 or 1.
3. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, which is a compound of Formula II:
4. The compound according to claim 3 , or a pharmaceutically acceptable salt thereof, which is selected from the group consisting of a compound of Formula IIa, Formula IIb, Formula IIc, Formula IId, Formula IIe and Formula IIf:
5. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, which is a compound of Formula III:
6. The compound according to claim 5 , or a pharmaceutically acceptable salt thereof, which is selected from the group consisting of a compound of Formula IIIa, Formula IIIb, Formula IIIc, Formula IIId and Formula IIIe:
7. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof,
wherein
n is 2 or 3.
8. The compound according to claim 7 , or a pharmaceutically acceptable salt thereof, which is a compound of Formula IVa, Formula IVb or Formula IVc:
9. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 is F.
10. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 is CH 3 .
11. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5 is H.
12. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5 is C 1 -C 4 alkyl substituted with 0, 1, 2 or 3 F.
13. The compound according to claim 1 , which is:
(−)-3-[(2,3-DIFLUOROPHENYL)(FLUORO)METHYL]AZETIDINE,
(+)-3-[(2,3-DIFLUOROPHENYL)(FLUORO)METHYL]AZETIDINE,
(−)-3-[(3,5-DIFLUOROPHENYL)(FLUORO)METHYL]AZETIDINE,
(+)-3-[(3,5-DIFLUOROPHENYL)(FLUORO)METHYL]AZETIDINE,
3-[(3,4-DIFLUOROPHENYL)(FLUORO)METHYL]AZETIDINE,
3-[(2,5-DIFLUOROPHENYL)(FLUORO)METHYL]AZETIDINE,
3-[(2,6-DIFLUOROPHENYL)(FLUORO)METHYL]AZETIDINE,
3-[(2,4-DIFLUOROPHENYL)(FLUORO)METHYL]AZETIDINE,
3-[FLUORO(2,3,5-TRIFLUOROPHENYL)METHYL]AZETIDINE,
3-[FLUORO(2,4,6-TRIFLUOROPHENYL)METHYL]AZETIDINE,
3-[FLUORO(2,3,4-TRIFLUOROPHENYL)METHYL]AZETIDINE,
3-[FLUORO(3,4,5-TRIFLUOROPHENYL)METHYL]AZETIDINE,
3-[(3,5-DIFLUOROPHENYL)(FLUORO)METHYL]AZETIDINE,
3-[(2,3-DIFLUOROPHENYL)(FLUORO)METHYL]AZETIDINE,
3-[(2,3-DIFLUOROPHENYL)(FLUORO)METHYL]-1-METHYLAZETIDINE,
3-[(2,3-DIFLUOROPHENYL)(FLUORO)METHYL]-1-ETHYLAZETIDINE,
3-[(2,3-DIFLUOROPHENYL)(FLUORO)METHYL]-1-PROPYLAZETIDINE,
3-[(3,5-DIFLUOROPHENYL)(FLUORO)METHYL]-1-METHYLAZETIDINE,
3-[(3,5-DIFLUOROPHENYL)(FLUORO)METHYL]-1-ETHYLAZETIDINE,
3-[(3,5-DIFLUOROPHENYL)(FLUORO)METHYL]-1-PROPYLAZETIDINE,
3-[FLUORO(2,3,5-TRIFLUOROPHENYL)METHYL]-1-METHYLAZETIDINE,
1-ETHYL-3-[FLUORO(2,3,5-TRIFLUOROPHENYL)METHYL]AZETIDINE,
3-[FLUORO(2,3,5-TRIFLUOROPHENYL)METHYL]-1-PROPYLAZETIDINE,
1-ETHYL-3-[FLUORO(2,3,4-TRIFLUOROPHENYL)METHYL]AZETIDINE,
3-[FLUORO(2,3,4-TRIFLUOROPHENYL)METHYL]-1-PROPYLAZETIDINE,
1-ETHYL-3-[FLUORO(3,4,5-TRIFLUOROPHENYL)METHYL]AZETIDINE,
3-[FLUORO(3,4,5-TRIFLUOROPHENYL)METHYL]-1-PROPYLAZETIDINE,
3-[FLUORO(2,3,5,6-TETRAFLUORORPHENYL)METHYL]AZETIDINE,
3-[FLUORO(PENTAFLUOROPHENYL)METHYL]AZETIDINE,
3-[FLUORO(2,3,5,6-TETRAFLUOROPHENYL)METHYL]-1-METHYLAZETIDINE,
1-ETHYL-3-[FLUORO(2,3,5,6-TETRAFLUOROPHENYL)METHYL]-AZETIDINE, or
3-[FLUORO(2,3,5,6-TETRAFLUOROPHENYL)METHYL]-1-PROPYLAZETIDINE
or a pharmaceutically acceptable salt of any of the foregoing compounds.
14. The compound according to claim 1 , which is:
(−)-3-[(2,3-DIFLUOROPHENYL)(FLUORO)METHYL]AZETIDINE,
(−)-3-[(3,5-DIFLUOROPHENYL)(FLUORO)METHYL]AZETIDINE, or
(−)-3-[FLUORO(2,3,5-TRIFLUOROPHENYL)METHYL]AZETIDINE,
or a pharmaceutically acceptable salt of any of the foregoing compounds.
15. The compound according claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I is a (−)-enantiomer.
16. The compound according to claim 1 which is a pharmaceutically acceptable salt of the compound of Formula I.
17. A pharmaceutical composition, comprising a therapeutically effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient and/or diluent.
18. A method for treatment of a disease, disorder and/or condition which is responsive to modulation of monoamines in the cerebral cortex which method comprises the step of administering a therapeutically effective amount of a compound of the compound according to claim 1 , or a pharmaceutically acceptable salt thereof, to a patient in need thereof,
wherein said disease, disorder and/or condition is selected from the group consisting of dementia, age-related cognitive impairment, cognitive impairment associated with neurodegenerative disorders and/or diseases, autism spectrum disorders, affective disorders, schizophrenia, anxiety disorders, attention deficit hyperactivity disorder (ADHD) and movement disorders.
19. The method according to claim 18 , wherein said disease, disorder and/or condition is selected from the group consisting of dementia, age-related cognitive impairment and schizophrenia.
20. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein one or more hydrogen atoms in Formula I are replaced with one or more deuterium atoms.
21. The compound according to claim 1 , which is:
(−)-3-[(3,5-DIFLUOROPHENYL)(FLUORO)METHYL]AZETIDINE,
or a pharmaceutically acceptable salt thereof.
22. The compound according to claim 1 , which is:
(−)-3-[FLUORO(2,3,5-TRIFLUOROPHENYL)METHYL]AZETIDINE,
or a pharmaceutically acceptable salt thereof.
23. The method according to claim 18 , wherein the method comprises the step of administering a therapeutically effective amount of a compound of the compound according to claim 21 .
24. The method according to claim 23 , wherein said disease, disorder and/or condition is selected from the group consisting of dementia, age-related cognitive impairment and schizophrenia.
25. The method according to claim 18 , wherein the method comprises the step of administering a therapeutically effective amount of a compound of the compound according to claim 22 .
26. The method according to claim 25 , wherein said disease, disorder and/or condition is selected from the group consisting of dementia, age-related cognitive impairment and schizophrenia.